Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
CANDESARTAN CILEXETIL; HYDROCHLOROTHIAZIDE
APOTEX INC
C09DA06
CANDERSARTAN AND DIURETICS
32MG; 25MG
TABLET
CANDESARTAN CILEXETIL 32MG; HYDROCHLOROTHIAZIDE 25MG
ORAL
100
Prescription
ANGIOTENSIN II RECEPTOR ANTAGONISTS
Active ingredient group (AIG) number: 0244181003; AHFS:
APPROVED
2012-10-30
_APO-CANDESARTAN/HCTZ Product Monograph_ Page 1 of 39 PRODUCT MONOGRAPH PR APO-CANDESARTAN/HCTZ candesartan cilexetil/hydrochlorothiazide tablets USP 16 mg / 12.5 mg, 32 mg / 12.5 mg and 32 mg / 25 mg Angiotensin II AT 1 Receptor Blocker + Diuretic APOTEX INC. DATE OF REVISION: 150 SIGNET DRIVE OCTOBER 3, 2019 TORONTO, ONTARIO M9L 1T9 SUBMISSION CONTROL NO.: 231959 _APO-CANDESARTAN/HCTZ Product Monograph_ Page 2 of 39 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ............................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS ....................................................................................................... 3 WARNINGS AND PRECAUTIONS ....................................................................................... 4 ADVERSE REACTIONS ...................................................................................................... 9 DRUG INTERACTIONS ......................................................................................................14 DOSAGE AND ADMINISTRATION .....................................................................................18 OVERDOSAGE ...................................................................................................................19 ACTION AND CLINICAL PHARMACOLOGY ......................................................................20 STORAGE AND STABILITY................................................................................................23 DOSAGE FORMS, COMPOSITION AND PACKAGING ......................................................23 PART II: SCIENTIFIC INFORMATION ....................................................................................25 PHARMACEUTICAL INFORMATION .............................................................................. Կարդացեք ամբողջական փաստաթուղթը